CCL11 Blockade
CCL11 / eotaxin-1 blockade (lowering a pro-ageing chemokine)
Written by Aaron CuhaReviewed Sep 2026
Also known as: CCL11, Eotaxin-1, Eotaxin, Anti-eotaxin
A chemokine that rises with age in human plasma and impairs neurogenesis in mice. There is human observational data linking it to cognition, and no trial of blocking it in anyone.
Overview
CCL11, also called eotaxin-1, came out of the 2011 Nature parabiosis study that founded the pro-ageing factor field. Using heterochronic parabiosis, the authors showed that blood-borne factors in an old systemic environment suppress adult neurogenesis and impair learning and memory in young mice. Screening for the responsible factors identified chemokines including CCL11 whose plasma levels correlated with reduced neurogenesis in heterochronic parabionts and aged mice, and which were increased in the plasma and cerebrospinal fluid of healthy ageing humans. Raising CCL11 in young mice by peripheral injection decreased adult neurogenesis and impaired learning and memory, which is the causal step.
The human record is observational. In a 2018 study across two French cohorts, 515 urban dwellers from 3C-Bordeaux and 318 rural dwellers from the AMI cohort had plasma CCL11 measured by immunoassay and cognition measured by Mini-Mental State Examination. CCL11 was markedly higher in rural than urban dwellers, median 145 versus 103 pg/mL, and after adjustment for confounders was negatively associated with cognitive performance in rural dwellers but not in urban dwellers. That split result is the honest finding: an association in one population and not the other, from a cross-sectional design that cannot establish direction.
A separate and practically relevant human observation is that CCL11 is measurable in transfusion blood products and rises with donor age, reported in 2017.
No one has run a trial of blocking CCL11 in a human. The intervention concept, lowering or neutralising the chemokine, exists only as a concept.
Mechanism of action
In mice, raising peripheral CCL11 decreases adult hippocampal neurogenesis and impairs learning and memory, and reducing CCL11 mediates part of the benefit of environmental enrichment in the aged hippocampus. In humans, the established biology is the ordinary immunological one: CCL11 is an eosinophil chemoattractant acting through CCR3, central to allergic and eosinophilic inflammation. The connection between that role and the cognitive associations seen in human cohorts has not been worked out, and no human intervention has tested it.
Human evidence
Observational only. CCL11 has been measured in human plasma, cerebrospinal fluid and donated blood products, and higher levels have been associated with worse cognition in one of two cohorts studied together. No human has been given a CCL11-blocking intervention for ageing or cognition.
- The 2011 Nature paper reports that CCL11 is increased in the plasma and cerebrospinal fluid of healthy ageing humans. That is a human measurement inside an otherwise animal study.
- Experimental Gerontology 2018: 833 community-dwelling older adults across two French cohorts. Plasma CCL11 was significantly higher in rural (median 145 pg/mL) than urban dwellers (median 103 pg/mL), and after adjustment for confounders was negatively associated with Mini-Mental State Examination score in the rural cohort but not the urban one.
- Frontiers in Aging Neuroscience 2017: CCL11 is detectable in transfusion blood products and rises with donor age.
- No interventional human study of CCL11 blockade for any ageing or cognitive indication is registered or published.
What this does not tell you: A cross-sectional association in one of two cohorts is weak evidence and the authors present it as such. It cannot tell you whether high CCL11 causes cognitive decline, whether cognitive decline raises CCL11, or whether something else raises both. CCL11 is an inflammatory chemokine and correlates with inflammation generally, which is itself associated with worse cognition. Nobody has blocked it in a person, so nothing is known about whether doing so is safe or useful, and a chemokine central to eosinophil trafficking would not be blocked without consequences for allergic and antiparasitic immunity.
Reading the research record
CCL11 is the first identified pro-ageing blood factor and the reason this half of the field exists at all, so its record is worth reading precisely. The mouse causal evidence is real: injecting CCL11 into young mice impaired neurogenesis and memory, and reducing it accounts for part of the benefit of environmental enrichment. The human evidence is measurement.
What has not happened in fifteen years is a blockade trial. There is a plausible reason: anti-CCL11 and anti-CCR3 agents were developed for allergic and eosinophilic disease, a much clearer commercial path than cognitive ageing, and repurposing one for an ageing indication would require an endpoint and a trial size nobody has funded. That is an economic explanation for a thin record, not a finding that blockade would fail, and it equally is not evidence that it would work.
The transfusion finding deserves its own mention because it is the one part of this literature with an immediate practical edge: CCL11 is present in banked blood products and rises with donor age. That observation is about a product millions of people receive, and no clinical consequence has been demonstrated from it either way.
The evidence, charted
Fig. 1 · evidence composition
2of 4 citations (50%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 2011 to 2021, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Animal2011
The ageing systemic milieu negatively regulates neurogenesis and cognitive function
Mouse, with a human measurement component. Heterochronic parabiosis showed that an old systemic environment or plasma from old mice decreased synaptic plasticity and impaired contextual fear conditioning and spatial learning in young mice. CCL11 was identified as a chemokine whose plasma levels correlated with reduced neurogenesis, and which is increased in the plasma and cerebrospinal fluid of healthy ageing humans. Increasing peripheral CCL11 in young mice decreased neurogenesis and impaired learning and memory. NIH funded.
Nature - Animal2021
Reduced ccl11/eotaxin mediates the beneficial effects of environmental stimulation on the aged hippocampus
Mouse. Reduced CCL11 mediates part of the benefit of environmental enrichment on the aged hippocampus, which is the strongest causal evidence that lowering this chemokine is the operative change rather than a correlate.
Brain, Behavior, and Immunity - Human2018
Association between plasma CCL11 (eotaxin-1) and cognitive status in older adults: Differences between rural and urban dwellers
833 community-dwelling older adults: 515 urban from the 3C-Bordeaux cohort and 318 rural from the AMI cohort, with plasma CCL11 by immunoassay and Mini-Mental State Examination as the cognitive measure. CCL11 was higher in rural dwellers, median 145 pg/mL (IQR 115 to 201) versus 103 pg/mL (IQR 85 to 129), p < 0.001. After adjustment, CCL11 was negatively associated with cognitive performance in rural dwellers but not in urban dwellers. Cross-sectional, so direction of effect cannot be established.
Experimental Gerontology - Human2017
The "Aging Factor" Eotaxin-1 (CCL11) Is Detectable in Transfusion Blood Products and Increases with the Donor's Age
Human blood products. CCL11 is detectable in transfusion blood products and its concentration increases with the age of the donor. A practical human observation about a widely used medical product, and the reason donor age is discussed in this field at all.
Frontiers in Aging Neuroscience
Frequently asked questions
Does CCL11 cause cognitive decline in people?
Not shown. CCL11 rises with age in human plasma and cerebrospinal fluid, and one study of 833 older adults found higher levels associated with lower cognitive scores in rural but not urban dwellers. That is a cross-sectional association in one of two cohorts, which cannot establish cause. The causal evidence, that raising it impairs neurogenesis and memory, is in mice.
Can you block CCL11?
Not as a treatment anyone has tested for ageing. No CCL11-blocking therapy is approved for any indication and no trial of blocking it for cognition or ageing is registered. The intervention concept exists; the intervention does not.
Does donor age matter for a blood transfusion?
CCL11 is detectable in transfusion blood products and its level rises with the donor's age, which is a measured human fact. No clinical consequence has been demonstrated from that, in either direction, and transfusion practice is not based on it.